Another Insulin Closer to FDA Assessment

(MedPage Today) -- Once-daily insulin peglispro proved non-inferior to insulin glargine (Lantus) in two of the late-stage trials in the IMAGINE program, drugmaker Eli Lilly announced.

Source: MedPage Today Primary Care - September 9, 2014 Category: Primary Care Source Type: news